First Tracks Biotherapeutics, newly independent after its April 2026 spin-off from AnaptysBio, reported a Q1 2026 net loss reflecting robust R&D investment typical of early-stage biotechs. The company leverages a proprietary intellectual property portfolio acquired from AnaptysBio, supported by collaborations such as the Vanda Pharmaceuticals partnership, which provides milestone-based revenues. Positioned within the capital-intensive and competitive biotherapeutics sector, its future growth will heavily depend on advancing clinical programs and unlocking milestone payments. Its strong cash position offers runway to support operational development but underscores typical early-stage risks around funding continuity and execution as an independent entity.